CPX-351: Interim Phase II data

Interim data from 85 patients ages 60-75 with newly diagnosed AML in the open-label U.S. and Canadian Phase II CLTR0308-204 trial showed that CPX-351 resulted in a 61.4% complete remission rate vs. 50% for standard cytarabine and daunorubicin. The safety profile of CPX-351 was similar to that of standard cytarabine and daunorubicin. ...